

# FEASIBILITY STUDY ON IMPLEMENTATION OF DOSE **BANDING IN A TEACHING HOSPITAL**

E. Fargier<sup>1</sup>, M. Durand<sup>1</sup>, I. Federspiel<sup>1</sup>, MD. Desruet<sup>1</sup>, A. Lemoigne<sup>1</sup>, B. Allenet<sup>1</sup>, L. Foroni<sup>1</sup> <sup>1</sup> CHU Grenoble - Pharmacy, Boulevard Chantourne 38700 La Tronche, France



## Background

Dose banding (DB) is a system whereby, through agreement between prescribers and pharmacists, chemotherapy doses calculated on body surface area (BSA) are rounded up or down to predetermined standard doses (SD) with variance limit of +/- 5%. In our hospital, over **30,000 preparations of chemotherapy per year** are made. Implementation of DB could reduce patient waiting time and improve capacity planning of our cytotoxic preparation unit (CPU).

**Objective** 

# **Setting and Method**

Feasibility study on the implement of DB in our CPU

**Phase I** : Literature review of DB to identify selection criteria and method of assigning dose bands.

- **Phase II:** Retrospective analysis of 2013's production in CPU
- to identify cytotoxic drugs candidates and select SD

#### Results

## **SELECTION CRITERIA**

- Frequency of preparation ( > 250/year)
- Physicochemical stability after reconstitution (> 7days)
- **Opportunity for savings**
- 5 SD should cover at least 60% of preparation

#### **Selection dose: « TARGET DOSE » based banding**

#### **II. CYTOTOXIC DRUGS CANDIDATES**

On the 70 pharmaceutical specialties prepared in our CPU, **6 were eligible:** 

- Cyclophosphamide
- Cytarabine
- Gemcitabine
- Calcium Folinate
- Paclitaxel
- 5-Fluorouracile (5-FU)



The simulation was made with paclitaxel, 5-FU bolus injection (400mg/m<sup>2</sup>), and 5- FU 48-hour continuous infusion (2400 mg/m<sup>2</sup>)

5-FU Bolus injection (400mg/m <sup>2</sup> )					5-FU 48-hour continuous infusion						Paclitaxel				
					(2400mg/m²)							ΝΛογ	Volume		
SD (mg)	Min	Max	Volume		SD (mg)	Min	Max	Volume (ml)		SD (mg)	Min	Max	(ml)		
			(ml)							105	100	110	17,5		
500	475	525	10		3500	3325	3675	70		120	114	126	20		
600	570	630	12		3900	3705	4095	78		135	129	141	22,5		
700	665	735	14		4300	4085	4515	86		150	143	157	25		
800	760	840	16		4700	4465	4935	94	-	165	158	173	27,5		
4 SD -	> 69,5% of	f standard	isation		4 SD	→ 79% of	standardis	sation		<b>5 SD</b>	→ 65% of	standardis	sation		
						Concl	usions								

	(400mg/	/m²)											
		(400mg/m <sup>2</sup> )					(2400mg/m <sup>2</sup> )					ΝΛογ	Volume
	Min	Max	Volume (ml)		SD (mg)	Min	Max	Volume (ml)		SD (mg)	Min	Max	(ml)
SD (mg)		Ινίαχ								105	100	110	17,5
500 4	475	525	10		3500	3325	3675	70		120	114	126	20
<b>600</b> 5	570	630	12		3900	3705	4095	78		135	129	141	22,5
700 6	665	735	14		4300	4085	4515	86		150	143	157	25
800 7	760	840	16	-	4700	4465	4935	94		165	158	173	27,5
4 SD → 69	9,5% of st	tandardi	sation		<b>4 SD</b>	→ 79% of	standardis	ation		<b>5 SD</b>	→ 65% of	standardis	ation
						Concl	usions						

5-FU Bolus injection					5-FU 48-hour continuous infusion					Paclitaxel				
(400mg/m <sup>2</sup> )					(2400mg/m <sup>2</sup> )						Min	ΝΛογ	Volume	
	Min	Max	Volume		SD (mg)	Min	Max	Volume (ml)		SD (mg)	Min	Max	(ml)	
SD (mg)			(ml)							105	100	110	17,5	
500	475	525	10		3500	3325	3675	70		120	114	126	20	
600	570	630	12		3900	3705	4095	78	-	135	129	141	22,5	
700	665	735	14		4300	4085	4515	86		150	143	157	25	
800	760	840	16		4700	4465	4935	94		165	158	173	27,5	
4 SD -	→ 69,5% of	f standard	isation		4 SD	→ 79% of	standardis	sation		5 SD	→ 65% of	standardis	sation	
						Concl	usions							
						Conci	usions							

before implementation, this DB project should be approved by the medical starr and some practical constraints such as software, system management, storage, control should be developed.

On the other hand, status of these preparations is not well established by health authorities in France. They can be considered as hospital preparations (authorization request, statement, and respect of Good Manufacturing Practice) or as compounded medications requiring an early prescription.

<u>**References:**</u> 1) A Gillian. Toolkit: how to implement dose-banding of chemotherapy. Cancer Network Pharmacists Forum 2008 2) Plumridge RJ, Sewell GJ. Dose banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health-Syst Pharm, 2001: 58 (18): 1760-1764.